Privacy Policy

Effective Date: April 4, 2021

 We at Pyxis Oncology (“Pyxis”) know you care about how your personal information is used and shared, and we take your privacy seriously.  Please read the following to learn more about our Privacy Policy. This Privacy Policy applies to the operation of this website (“Site”). By using or accessing the Site in any manner, you acknowledge that you accept the practices and policies outlined in this Privacy Policy, and you hereby consent that we will collect, use, and share your information in the following ways.

1. What does this Privacy Policy Cover?

This Privacy Policy covers our treatment of personally identifiable information (“Personal Information”) that we gather when you are accessing or using our Site, but not to the practices of companies we do not own or control, or people that we do not manage. We gather various types of Personal Information from our users, as explained in more detail below.

Our Site is not intended to attract children, and we do not knowingly collect any Personal Information of anyone under the age of 13. If you believe your child is using our Site, please contact us online in the “Contact Us” section of our Site, so we can investigate and delete any applicable data.

2. What Information Does Pyxis Collect?

Categories of Personal Information We Collect:

  • Personal Identifiers. Contact details such as name, phone number, email address, postal address or mobile number.
  • Internet or Similar Network Activity Information.
    • Technical information collected from your computer or mobile device (e.g. your IP address, browser type, operating system)
    • Information about your usage of our Site (e.g. the pages you visit, the search terms you use, information about how often you connect to the Site, and the pages you visit on the Site)
    • Information which we may generate as a result of your use of our Site.
  • Other Personal Information. Any personal information that you choose to provide in correspondence and any communications with us and that we need to retain in order to manage and/or address our communications with, or requests from, you or to comply with our legal obligations.

The following section provides additional information about how we collect your Personal Data.

Information Collected Automatically

The Site uses cookies and similar technologies such as pixel tags, web beacons, clear GIFs, and JavaScript (collectively, “Cookies”) to enable our servers to recognize your web browser and tell us how and when you visit and use our Site, to analyze trends, learn about our user base and operate and improve our Site. Cookies are small pieces of data– usually text files – placed on your computer, tablet, phone, or similar device when you use that device to visit our Site. We may also supplement the information we collect from you with information received from third parties, including third parties that have placed their own Cookies on your device(s). Please note that because of our use of Cookies, the Site does not support “Do Not Track” requests sent from a browser at this time.

We use the following types of Cookies:

  • Strictly Necessary Cookies. Necessary Cookies enable core functionality. The Site cannot function properly without these Cookies, and these Cookies can only be disabled by changing your browser preferences.
  • Functional Cookies. These Cookies enable the Site to provide enhanced functionality and personalization. Functional Cookies are used to record your choices and settings regarding our Site, maintain your preferences over time and recognize you when you return to our Site. These Cookies help us to personalize our content for you, and remember your preferences (for example, your choice of language or region).  They may be set by us or by third party providers whose services we have added to our Site. If you do not allow these Cookies, some or all of the related services may not function properly. 
  • Performance/Analytical Cookies. Performance/Analytical Cookies allow us to understand how visitors use our Site such as by collecting information about the number of visitors to the Site, what pages visitors view on our Site and how long visitors are viewing pages on the Site. For example, Google, Inc. (“Google”) uses cookies in connection with its Google Analytics services. Google’s ability to use and share information collected by Google Analytics about your visits to the Site is subject to the Google Analytics Terms of Use and the Google Privacy Policy. You have the option to opt-out of Google’s use of cookies by visiting the Google advertising opt-out page at www.google.com/privacy_ads.html or the Google Analytics Opt-out Browser Add-on at https://tools.google.com/dlpage/gaoptout/. Performance/Analytical Cookies allow us to analyze our Site, which helps us to improve the way our Site works, for example, by ensuring that users can find what they are looking for easily.  All information these cookies collect is aggregated and therefore anonymized.

You can decide whether or not to accept Cookies through your internet browser’s settings. Most browsers have an option for turning off the Cookie feature, which will prevent your browser from accepting new Cookies, as well as (depending on the sophistication of your browser software) allow you to decide on acceptance of each new Cookie in a variety of ways. You can also delete all Cookies that are already on your computer. If you do this, however, you may have to manually adjust some preferences every time you visit a site and some of the services and functionalities may not work.

To explore what Cookie settings are available to you, look in the “preferences” or “options” section of your browser’s menu. To find out more information about Cookies, including information about how to manage and delete Cookies, please visit https://ico.org.uk/for-the-public/online/cookies/ or http://www.allaboutcookies.org/.

Pyxis uses Personal Information to contact you when necessary, to respond to your inquiries for additional information, to provide additional information according to your preferences and for our other business purposes.  Sometimes this information is used to send you information about Pyxis and its products, services and business partners.  At your election at any time, you may choose to stop receiving future communications from Pyxis (see below).

3. How We Use Your Personal Data

We process Personal Data to operate, improve, understand and personalize our Site. We use Personal Data for the following purposes:

  • To meet or fulfill the reason you provided the information to us.
  • To communicate with you about the Site, including Site announcements or updates.
  • To provide support and assistance for the Site.
  • To create and manage your account or other user profiles.
  • To personalize website content and communications based on your preferences.
  • To process transactions.
  • To respond to user inquiries and fulfill user requests.
  • To improve and develop the Site, including testing, research, analysis and development.
  • To protect against or deter fraudulent, illegal or harmful actions and maintain the safety, security and integrity of our Site.
  • To comply with our legal or contractual obligations and resolve disputes
  • To respond to law enforcement requests and as required by applicable law, court order, or governmental regulations.
  • For any other business purpose stated when collecting your Personal Data or as otherwise set forth in applicable data privacy laws.

We will not collect additional categories of Personal Data or use the Personal Data we collected for materially different, unrelated, or incompatible purposes without providing you notice.

As noted in the list above, we may communicate with you if you’ve provided us the means to do so. Also, we may receive a confirmation when you open an email from us, which helps us improve our Site.

4. Will Pyxis Share Any of the Personal Information it Receives?

Pyxis may freely use this information for its business purposes, and may disclose such information, in a form that does not personally identify you, to any other person or entity.  We may share statistical or aggregated non-personal information about our users with advertisers, business partners, sponsors and other third parties. This data is used to customize Pyxis website content and advertising to deliver a better experience to our users.  Pyxis may also share any information (personally identifiable or otherwise) it may have collected if Pyxis believes it is necessary to (a) comply with law or court order or (b) protect and/or defend Pyxis’s rights, safety, or property, or those of any other person or entity.  If we (or our assets) are acquired, or if we go out of business, enter bankruptcy, or go through some other change of control, personal information collected as described in this Privacy Policy could be one of the assets transferred to or acquired by a third party.

5. California Privacy Rights

While Pyxis does not provide personal information to third parties for their use in marketing, under California law, California residents have the right to opt-out of such use of their Personal Information if it occurred.

6. Changes to this Privacy Policy

Pyxis reserves the right to change or update this Privacy Policy at any time by posting a notice at the Site.  Information collected by the Service is subject to the Privacy Policy in effect at the time of use.

You may be able to add, update, delete, correct or otherwise change your information by contacting Pyxis, as provided below.

7. How to Contact Us

Please contact us if you have any questions or comments about our privacy practices, your privacy choices, including those related to our use of your Personal Information, or this Privacy Policy. You can always reach us online at https://pyxisoncology.com. You may contact us to delete, update, or correct the Personal Information that you provided to us through the website.

If you choose to contact us via mail at the address below, please provide your name, address, email address, along with your questions, comments, or requests.

Pyxis Oncology
Attn: Head of Legal
35 CambridgePark Drive, Suite 100-R
Cambridge, MA 02140
info@pyxisoncology.com

 

Christopher O’Donnell, Ph.D.

Director

Christopher O’Donnell, Ph.D. is a Partner at Pfizer Ventures and Executive Director, Pfizer Worldwide Research, Development & Medical. Chris has over 20 years of scientific leadership at Pfizer and a strong track record of delivering clinical candidates across multiple disease areas and modalities. Prior to Pfizer Ventures, Chris built and led the Applied Synthesis Technologies group within Pfizer Worldwide Research & Development organization to accelerate the delivery of Pfizer’s small molecule portfolio. Prior to that, Chris built and led Pfizer’s Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in 7 conjugates entering clinical development for many different cancer indications and this technology is at the foundation of PYX-201 and PYX-203. Chris started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates, with the most advanced being the AMPA positive allosteric modulator in Phase II that was licensed to Biogen. Chris has co-authored 60 peer reviewed manuscripts and is the inventor/co-inventor on 25 patents.

Chris earned his BS in Chemistry from the University of Illinois-Urbana/Champaign and his Ph.D. in Chemistry from the University of Wisconsin-Madison and joined Pfizer after his post-doctoral research studies as an American Cancer Society Fellow at the University of California – Irvine.

Within Pfizer Ventures Chris is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently serves on the boards of Adapsyn Biosciences, ARKUDA Therapeutics, Pyxis Oncology, Storm Therapeutics (UK) and Strata Oncology. Chris previously served on the boards of Kymera Therapeutics (KYMR) and was a board observer of BioAtla Inc. (BCAB), Mitokinin, Morphic Therapeutic (MORF) and Petra Therapeutics.

Gotham Makker, M.D.

Director

Gotham Makker, M.D., serves as head of Strategic Investments at RTW Investments, LP (“RTW”). Gotham has more than 17 years of healthcare industry experience. Prior to joining RTW, Gotham served as CEO of Simran Investment Group, LLC, a privately held equity investment fund. Before Simran, Gotham was a healthcare portfolio manager and principal at Citadel Investment Group LLC, a position he held from 2002 to 2005. Prior to joining Citadel, Gotham served in various analyst roles at Oracle Partners LP, covering biotechnology and medical device sectors. He began his career on the life sciences investment banking team at Hambrecht & Quist.

Gotham serves on the board of directors of Rocket Pharmaceuticals.

Gotham received his MD from the University of Nebraska Medical School, and he completed the Sarnoff cardiovascular research fellowship at Columbia University, College of Physicians & Surgeons and at Harvard Medical School, Brigham & Women’s Hospital.

Christian Schetter, Ph.D.

Director

Christian has over 20 years’ experience in the life science industry. He is Executive Chairman of STipe Therapeutics, Chairman of Twelve Bio and a Non-Executive Director of Atox Bio, all Arix portfolio companies. Prior to joining Arix he was for four years CEO of Rigontec GmbH, a German Biotech start-up company in the immune oncology space. Christian lead Rigontec to a successful acquisition mid 2017 by MSD valuing EUR 115 MM in upfront payment and additional EUR 349 million in potential milestones. Between 2008 and 2014 Christian was President and CEO of Neovii Biotech, previously Fresenius Biotech. During his tenure one antibody product was brought to market and the indication for another product expanded. Christian was instrumental in selling Fresenius Biotech to the Neopharm Group, Israel, to form Neovii Biotech and positioning it as a successful standalone business. Before joining Fresenius, Christian was Senior Vice President, European Operations of Coley Pharmaceutical Group, Inc, a pioneer in the development of immunostimulatory oligonucleotides, and served as Managing Director of Coley GmbH. He was part of the leadership team which built Coley Pharmaceuticals from inception through multiple financing rounds, a NASDAQ IPO and, following a number of significant pharma deals, to a trade sale to Pfizer in 2007.

Before entering the life science industry Christian was successfully performing academic research at the Max Planck Institute in Martinsried, Germany. He received his undergraduate degree and PhD from the University of Cologne and did postdoctoral research in oncology and virology at the Scripps Research Institute in La Jolla, California.

John Flavin

Co-founder, Founding Chairman and Independent Director

John is co-founder and an independent Director of Pyxis Oncology, where he was founding Chairman. He is also the Founder and CEO of Portal Innovations, a life sciences venture development engine.  A seasoned life sciences executive and entrepreneur with over 20 years of experience in finance, operations, and innovation, John has co-founded and scaled several life sciences companies as President and CFO such as Advanced Life Sciences and MediChem Life Sciences. Mr. Flavin has also co-founded and led transformative life sciences incubators including MATTER and the Polsky Center for Entrepreneurship and Innovation at the University of Chicago. He has completed numerous public and private capital financings totaling over $300 million including 2 NASDAQ IPOs and has raised over $135 million in philanthropic and corporate funding to support university technology commercialization and venture start-up activities.  He received his B.S. in Business Administration from Marquette University and his M.B.A. in Finance from Lewis University. 

Lucio Iannone, Ph.D.

Director

Lucio Iannone is an investor at Leaps by Bayer, the investment arm of the global life sciences company Bayer. Lucio is responsible for developing investment cases and deal execution. He is also involved in the sourcing, screening, and mentoring of companies with game-changing science. As an investor, Lucio is also serving as board member for Khloris Biosciences, Vesigen Therapeutics , Immunitas Therapeutics, eGenesis, Azitra, Kojin Therapeutics and Axxam. Before joining Leaps by Bayer, he had several senior roles in biotechnology companies and venture capital firms. He has experience with molecular biology, cell & gene therapy technologies and their application in oncology and other therapeutic fields. Lucio obtained his Ph.D. in Medicine at the Imperial College of London.

David Steinberg

Founding CEO and Chairman

David is co-founder and Chairman of Pyxis Oncology, where he was founding CEO, and serves as a General Partner at Longwood Fund. Previously, David was co-founder and Chief Innovation Officer at PureTech Health, (LSE: PRTC), where he focused on biotech venture creation and investing. David has co-founded and served as CEO and founder of several biotech companies, including Vor Biopharma (NASDAQ:VOR) Be Biopharma, Vedanta Biosciences, Endra Life Sciences Inc. (NASDAQ: NDRA), and Entrega Biosciences, and co-founded ResTORbio (NASDAQ: TORC). Prior to that David worked in biopharma strategy consulting at Boston Consulting Group and Vertex Partners, and in R&D at P&G Pharmaceuticals. He received his M.B.A. from the University of Chicago Booth School of Business and holds a B.A. in biology from Cornell University.

Ritu Shah, PMP

Chief Operating Officer

Ritu is the Chief Operating Officer at Pyxis Oncology. Ritu has over 20 years of experience in the pharmaceutical and biotech industry specializing in portfolio management and strategic planning. Prior to joining Pyxis, Ritu served as the Vice President of Business Operations and Program Management of Levo Therapeutics where she led the operations for the Phase 3 trial of Prader-Willi syndrome, a rare disease. Prior to Levo, Ritu was the Chief of Staff to the CEO and Vice President of Program Management for AveXis, a biotech gene therapy company focusing on SMA, and led the integration following the $8.7B acquisition by Novartis. Prior to AveXis, Ritu spent 8 years at Baxter, Baxalta, and Shire in various executive roles leading patient advocacy, commercial, research and development, supply chain, and global operations. Ritu started her career at Accenture where she spent over a decade in management consulting focusing on R&D and supply chain projects across manufacturers, wholesalers, and retailers.

Ritu earned her B.Sc. from University of Notre Dame in the Department of Chemical Engineering and graduated summa cum laude. Ritu is certified as a Project Management Professional, PMP. Ritu is also involved in her community and serves as a Board member of an entrepreneurial incubator program.

Steve Monks

Chief Technical Officer

Steve is the Chief Technical Officer at Pyxis Oncology. Prior to joining Pyxis, Steve was an independent consultant advising small to medium biotech companies in the oncology, vaccine, and tissue repair spaces on CMC (chemistry, manufacturing, and controls), Quality, and Regulatory strategies. Prior to this, Steve served as Senior Vice President of Development at Aura Biosciences where he spearheaded all product technical development efforts for their Virus-Like drug conjugate AU-011. Prior to Aura, Steve was a member of the executive leadership team at Agenus, where he was responsible for internal and external cGMP manufacturing, warehousing and distribution, and the analytical and process development functions across the entire Agenus pipeline.

Steve received his Ph.D. from The University of Melbourne and a BSc with first-class honors in Zoology from the University of Queensland, Australia.

James Mutamba, Ph.D.

Vice President of Business and Corporate Development

Dr. James Mutamba is the Vice President of Business and Corporate Development at Pyxis Oncology. Prior to joining Pyxis, Dr. Mutamba was a Principal at Longwood Fund, where he was responsible for building and supporting portfolio companies, including Pyxis Oncology. Prior to Longwood he was a Senior Associate at PureTech Health where he co-founded Commense, Inc., a microbiome-based maternal and childhood health company. Dr. Mutamba was also a co-founder and inventor in Glyph Biosciences, an immune-focused company targeting novel lymphatic system biology, and Calix Biopharma, a company developing engineered exosomes for novel drug delivery applications. Prior to joining PureTech, Dr. Mutamba was a strategy consultant at ClearView Healthcare Partners and played multiple roles in research and product development at Pathogenica, Inc., a biotech startup out of Harvard University. 

Dr. Mutamba earned his Ph.D. from MIT in the Department of Biological Engineering and completed coursework at the MIT Sloan School of Management. He received his BS in Biochemistry from UNCG where he graduated summa cum laude and Phi Beta Kappa. 

Ronald Herbst, Ph.D.

Chief Scientific Officer

Dr. Ronald Herbst is the Chief Scientific Officer of Pyxis Oncology. Prior to joining Pyxis, Dr. Herbst was Vice President, Research & Development and Head of Oncology Research at MedImmune, the global biologics research and development arm of AstraZeneca, where he served as Chair of the Oncology Research Committee and as member of the MedImmune Research Leadership Team. Under his leadership, the oncology group brought 10 novel targets to the clinic in the areas of immunotherapy and antibody drug conjugates. Prior to that, Ronald focused on the company’s respiratory, inflammation and autoimmunity efforts, where he led the advancement of 4 novel molecules into the clinic, including one that is now approved by the US Food and Drug Administration. 

Before joining MedImmune, Ronald was Senior Principal Investigator in oncology at DNAX, a Schering Plough biotechnology subsidiary. 

Ronald conducted his postdoctoral research in the Department of Biology at Stanford University.  He obtained his Ph.D. at the Ludwig-Maximilian University of Munich, with research conducted at the Max-Planck Institute of Biochemistry in Axel Ullrich’s Laboratory. Ronald has (co)-authored more than 100 publications and is co-inventor on 17 pending or granted patents. 

Robert Crane

Chief Financial Officer

Robert Crane is the Chief Financial Officer of Pyxis Oncology. Mr. Crane has 30 years of experience in the life sciences industry, including therapeutics, medical devices, and diagnostics. Mr. Crane has been involved with public and private firms in the U.S., Europe, and Asia, serving as chief financial officer at six U.S. public companies. He has listed companies on NASDAQ as well as the Australian Stock Exchange.

Mr. Crane has served as Chief Financial Officer plus stepping in to run manufacturing, quality, and business development when required. Mr. Crane has been responsible for several IPOs and numerous public and private financings with proceeds of over $1 billion plus partnerships and collaborations. He has also been responsible for the sale of multiple companies. Mr. Crane’s involvement includes growth-stage companies and turnarounds. Companies where Mr. Crane has been CFO include Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline Plc; I-STAT Corporation, Inc., which was acquired by Abbott Laboratories; Taris Biomedical, which was acquired by Allergan and Johnson & Johnson; InKine Pharmaceutical Company, Inc., which was acquired by Salix, Inc.; Olivo Laboratories which was acquired by Shiseido; Seragen, Inc., which was acquired by Ligand Pharmaceuticals, Inc.

Mr. Crane was previously a partner in the venture capital firm, Montgomery Ventures which invested in emerging healthcare and technology companies. He was also chairman of the American Bicycle Group, a premier manufacturer of high-end bicycles with brands including Litespeed, Merlin, and Quintana Roo.

Mr. Crane holds a Bachelor of Science in mechanical engineering from the Massachusetts Institute of Technology and a Masters of Business Administration from Stanford University.

Lara S. Sullivan, M.D.

Chief Executive Officer

Dr. Lara S. Sullivan is the Chief Executive Officer of Pyxis Oncology. Prior to joining Pyxis, Lara was Founder and President of SpringWorks Therapeutics (NASDAQ: SWTX), a clinical stage biopharmaceutical company spun-out from Pfizer. While at Pfizer, Lara led strategy, competitive intelligence and portfolio operations for the company’s early-stage R&D pipeline. Prior to joining Pfizer, Lara was an associate partner at McKinsey & Company, where she specialized in biopharmaceutical R&D productivity and efficiency. Lara also served as a principal at Paul Capital Partners, where she led due diligence for healthcare investments, and earlier in her career worked in healthcare equity research and healthcare municipal finance at Credit Suisse First Boston.

Lara holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School at the University of Pennsylvania, and a B.A. in Comparative Literature from Cornell University.